Metraipolis › archive › dc_20135af44360
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study — Europe PMC PMID:41292059
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41292059
- DOI
- 10.1111/iju.70281
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T06:52:19.975Z
- SHA-256 of the archived text
ee6c22487eafaea747eb6a1d6fc34be281fcd110934efa5c3970f46529682047- Stable URL of this page
https://metraipolis.com/documento/dc_20135af44360
How to cite
Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study — Europe PMC PMID:41292059 — Europe PMC (en), https://europepmc.org/article/MED/41292059 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_20135af44360 (Metraipolis archive dc_20135af44360, sha256 ee6c22487eafaea747eb6a1d6fc34be281fcd110934efa5c3970f46529682047)
BibTeX
@misc{dc20135af44360,
title = {Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study — Europe PMC PMID:41292059},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41292059},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_20135af44360; sha256 ee6c22487eafaea747eb6a1d6fc34be281fcd110934efa5c3970f46529682047},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41292059. Agents can read the archived copy with the MCP tool read_document.